Gilde Healthcare, an Utrecht, The Netherlands and Cambridge, Massachusetts-based venture capital firm, closed its fourth fund, at €250m ($285m).
Gilde Healthcare IV is backed by a mix of international investors including cornerstone investor Royal Philips (NYSE: PHG, AEX: PHIA)), Johnson & Johnson Innovation – JJDC, and fund-of-funds, sovereign funds such as Danish Growth Fund, endowments, family offices, entrepreneurs and Gilde partners.
The European Investment Fund participated through several of its funding programs including the European Recovery Program and Dutch Venture Initiative II.
A later stage and growth capital fund, it targets investments in innovative private scale-up opportunities in medtech, digital health and therapeutics both in Europe and North America.
It will make equity investments in a single portfolio company of between €15-25m.
Led by Pieter van der Meer, Managing Partner, Gilde Healthcare is organized along two business lines managing separate funds for innovative healthcare technology companies and lower mid-market healthcare services companies.
The firm has raised over €800m ($910 million) in dedicated healthcare funds and is actively looking to lead new private investments in medtech, digital health, therapeutics and healthcare services. In the last three years, Gilde exited 14 portfolio companies across its healthcare funds including:
– Definiens, a provider of image analysis software for digital pathology;
– Inovalabs, which markets portable oxygen concentrators for patients with respiratory conditions;
– ProFibrix, which developed a novel topical hemostatic agent to treat fast bleeding wounds;
– Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design;
– Santaris, which develops RNA-targeted drugs and
– Sapiens, a Dutch neuro-modulation company focused on deep brain stimulation for patients suffering from Parkinson’s disease.
FinSMEs
14/06/2016